It’s time to double-down on healthcare innovation, not stifle it by weakening global intellectual property standards.
In a not-so-shocking revelation, a recently leaked draft of the Trans-Pacific Partnership (TPP) intellectual property (IP) chapter turned up the fact that…surprise…the United States is fighting for its domestic industries in a trade agreement.
Without the Ex-Im Bank, American businesses and employees will compete on a very uneven playing field.
The charter of the Export-Import Bank of the U.S. (Ex-Im) expired at the end of June, disabling it from making any new loans unless Congress takes action now that it has returned from its July 4th recess. I have heard some Ex-Im opponents cheer this charter lapse as an “historic victory.” But the only thing that will be “historic” is the enormity of the blunder in failing to renew Ex-Im’s charter.
With global competitors expanding export credit to support their own companies, why would the Unites States unilaterally disarm the Ex-Im Bank?
With Congress in the midst of considering legislation to reauthorize the U.S. Export-Import (Ex-Im) Bank — its current authorization expires and thus must be extended by June 30, 2015 — comes fresh evidence reiterating the vital need for the Bank in providing export credit finance support for America’s exporters.
Speech as delivered to The Economic Club, Washington, DC, on June 17, 2015.
The TTIP and TPP will attract more foreign investment to our shores, bringing high-paying jobs with it.
Trade secret theft costs U.S. businesses hundreds of billions of dollars each year. U.S. trade secrets laws need to catch up with technological changes to protect manufacturers in an increasingly complex and competitive global landscape.
Technology and digitization are increasingly important drivers of manufacturing innovation and competitiveness, but also create a host of challenges and vulnerabilities when it comes to trade secrets protection.